Back to top
more

Galectin Therapeutics (GALT)

(Real Time Quote from BATS)

$3.36 USD

3.36
52,418

-0.02 (-0.59%)

Updated Apr 24, 2024 12:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock

by Zacks Equity Research

Galectin Therapeutics Inc. (GALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Galectin Therapeutics Inc. (GALT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y

by Zacks Equity Research

Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

Company News for Apr 15, 2021

by Zacks Equity Research

Companies in the news are: FRC, TV, GALT, DG

New Strong Sell Stocks for October 12th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

New Strong Sell Stocks for August 31st

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Galectin Therapeutics' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Galectin Therapeutics.

Kinjel Shah headshot

Small Drug Stock Outlook: Innovation Holds the Key to Growth

by Kinjel Shah

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

FibroGen (FGEN) Catches Eye: Stock Jumps 7.4%

by Zacks Equity Research

FibroGen (FGEN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for August 27th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

by Zacks Equity Research

Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

by Zacks Equity Research

Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.

Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance

by Zacks Equity Research

Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.

Conatus (CNAT) Completes Enrollment in Phase II NASH Study

by Zacks Equity Research

Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.

Ascendis Pharma Files IND for Hypoparathyroidism Candidate

by Zacks Equity Research

Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.

Alkermes Sinks as FDA Refuses to Approve Depression Drug

by Zacks Equity Research

Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).

AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA

by Zacks Equity Research

AVEO Oncology (AVEO) decides against filing NDA for Fotivda on recommendation of the FDA. The agency remains concerned with the overall survival data.

Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (GALT) Outperforming Other Medical Stocks This Year?

Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda

by Zacks Equity Research

Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.

    Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

      Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?

      by Zacks Equity Research

      Investors in Galectin Therapeutics (GALT) need to pay close attention to the stock based on moves in the options market lately.